Top 10 generics makers by 2012 revenue
The Hatch-Waxman Act shook up the generic drugs business in 1984, and almost 30 years later, it's safe to say the law had its desired effect. About 84% of the 4 billion prescriptions written each year are for generic drugs, saving patients and government programs billions of dollars a year. In other words, generic drugs are big business. And with a slew of blockbuster brands now off patent, it's a big business with growing pains.
As companies bulked up to take on copies of the world's best-selling drugs, a wave of mergers has swept the industry. Many credit Actavis CEO Paul Bisaro with starting that trend; then the Watson CEO, his 2012 takeover of Actavis sent a clear message of "go big or go home" reverberating throughout the generics business. Actavis hasn't stopped scouting for deals, and many of its peers have followed suit.
Peruse the Top 10 to find out how these trends and market forces are shaping the industry's biggest players--and vice versa. Read the report >>
Top 10 Drugmakers in Emerging Markets
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around the world. The answer, for both, was emerging markets. Drug spending would more or less stagnate in mature markets such as the United States and the European Union. But in the developing world, drug spending was just taking off.
Like miners rushing to California in the 1880s, drugmakers raced to capture their share of those markets. While cutting costs, shuttering facilities and laying off thousands in the U.S. and EU, pharma companies hired on in China, India, Mexico--to the point where laid-off sales reps joked about moving to Asia to find a pharma job. Read the full report >>
Top 15 Drug Launch Superstars
A year ago, FiercePharma published a list of drugs that missed when stepping on the up escalator. A heel got caught, or a sleeve. Bystanders hit the emergency stop button. For whatever reason, escalate they did not. We called it "Top 10 Drug Launch Disasters." It's still one of our most popular special reports. This year, we wanted to take a more positive approach.
So, herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience.
Check out the report >>
POPULAR COMMENT THREADS
GSK, Sanofi join Gates Foundation vaccine R&D initiative
Vaccine manufacturers are often criticized for investing in shots aimed at high-margin Western markets, while neglecting diseases affecting the developing world. This week, the Bill & Melinda Gates Foundation set up a project to spur development in neglected areas by cutting the financial risk of early research.
In August, a Wall Street analyst placed a headline-grabbing $0 price target on the stock of struggling cancer vaccine manufacturer Dendreon. Now, Dendreon has reportedly hired JP Morgan Chase to find someone who sees more value in the company and is willing to back their belief by acquiring the business.
The layoffs and cuts outlined by Merck earlier this month showed the faith it has in the vaccine unit to drive growth over the coming years. And this week brought fresh data to back its decision, with third-quarter results showing strong demand for vaccines propping up other struggling areas of the firm.
In August, Sanofi gave a first look at eagerly anticipated data from Phase III comparing its high-dose Fluzone vaccine with a standard jab. The data prompted Sanofi to talk up its chances of getting a label for superior efficacy data in people aged over 65, and this week it began making its case.
ACIP recommendation gives Novartis a new growth opportunity
The ACIP decision comes two months after the FDA expanded its label for the meningococcal vaccine. Menveo is now cleared for use in babies aged two months and older, and ACIP has recommended use in infants up to the age of 23 months, but only in certain instances.
Gates Foundation backs Brazilian measles and rubella vaccine
Brazil-based Bio-Manguinhos is working with the Bill & Melinda Gates Foundation to produce a combined measles and rubella vaccine for developing countries in Africa and other regions.
From Our Sister Sites
Diagnostics outfit CardioDx upped the high end of its planned IPO to $92 million and revealed some details about its envisioned offering.
NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.